Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials
This compilation provides an overview of Eli Lilly‘s recent clinical trial activity, encompassing up to 200 of their latest trials. Alongside these trials are potentially related publications, patents, and grant funding, which may include work from Eli Lilly or other entities exploring similar therapeutic areas. This resource aims to offer researchers, clinicians, investors, and the broader public insights into Eli Lilly’s current research and development pipeline. By presenting clinical trial details alongside related intellectual property and financial backing (regardless of origin), this compilation facilitates a broader understanding of Eli Lilly’s strategic focus and how it potentially compares to direct and indirect competitors in these therapeutic spaces. This information can be valuable for identifying emerging trends in drug development, assessing the commercial potential of specific research programs, and understanding the broader landscape of scientific contributions related to Eli Lilly’s clinical trials. (Last updated on: 2025-05-20)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate The Efficacy and Safety of LY3209590 As A Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. The study consists of a 1-week screening period, a 2-week lead-in period, a 52-week treatment period, and a 5-week safety follow-up period. The study will last up to 60 weeks. |
ELI LILLY | 2025-05-16 |
| 2 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating The Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months. |
PATRICIA WU; | 2025-05-15 |
| 3 | A Multiple-Ascending Dose Study to Investigate The Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 48 weeks excluding a screening period. |
STEVEN REYNOLDS; | 2025-05-13 |
| 4 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess The Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD). |
WEILY SOONG; | 2025-05-13 |
| 5 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate The Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks. |
ALMENA FREE; | 2025-05-13 |
| 6 | A Phase 1 Study to Further Investigate The Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the body’s absorption and processing of the study drug, the study drug’s effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants |
AMINA HAGGAG; | 2025-05-09 |
| 7 | SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab Vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum Vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing. |
MARSHALL SCHREEDER; | 2025-05-07 |
| 8 | A Phase 2b, Double-Blind Study to Investigate The Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks. |
ELI LILLY | 2025-05-06 |
| 9 | A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C), Multi-Dose, Phase 1 Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec. The study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected. The study will be conducted in three parts (A, B, and C). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC. The study will last up to approximately 11 weeks for Part A, 10 weeks for Part … |
OLIVER KLEIN; | 2025-05-06 |
| 10 | A Phase 1 Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 5 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period. |
OLIVER KLEIN; | 2025-05-02 |
| 11 | A Master Protocol to Investigate The Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight. |
JOSEPH LILLO; | 2025-05-01 |
| 12 | A Master Protocol to Investigate The Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2. |
ELI LILLY | 2025-04-30 |
| 13 | Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer’s Disease PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer’s disease (AD). |
ELI LILLY | 2025-04-25 |
| 14 | A Master Protocol for A Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA’s complete. |
ELI LILLY | 2025-04-25 |
| 15 | A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits. |
HUGH COLEMAN; | 2025-04-25 |
| 16 | LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years. |
ELI LILLY | 2025-04-25 |
| 17 | A Phase 1, Open-label, Single-arm Study to Investigate The Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants. |
ELI LILLY | 2025-04-25 |
| 18 | A Phase 1a/1b Study of LY4052031, An Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts – phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years. |
ELI LILLY | 2025-04-24 |
| 19 | A Phase 3, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks. |
ELI LILLY | 2025-04-23 |
| 20 | A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing The Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer – SUNRAY-02 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant. |
JORGE DIAZ; | 2025-04-23 |
| 21 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. |
KIMBALL JOHNSON; | 2025-04-23 |
| 22 | A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up. |
BRANDON LAWRENCE; | 2025-04-23 |
| 23 | A Phase 1/2 Study of The Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor. |
ELI LILLY | 2025-04-23 |
| 24 | A Phase 1, Open-label, Two-part Study to Investigate The Absorption, Metabolism, and Excretion, and The Absolute Bioavailability of [14C]-LOXO-292 in Healthy Male Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and extent of elimination of selpercatinib in healthy male participants. The study will last up to 59 days (Part 1) or 46 days (Part 2) including screening and 7-day safety follow-up. |
ELI LILLY | 2025-04-23 |
| 25 | FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse. |
ELI LILLY | 2025-04-22 |
| 26 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating The Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks. |
KRISTIN CASTORINO; | 2025-04-22 |
| 27 | A Phase 1a/1b Study of The Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years. |
ELI LILLY | 2025-04-22 |
| 28 | A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years. |
ELI LILLY | 2025-04-22 |
| 29 | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation. |
ELI LILLY | 2025-04-22 |
| 30 | Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib. |
ELI LILLY | 2025-04-22 |
| 31 | A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G. |
AMINA HAGGAG; | 2025-04-22 |
| 32 | A Phase 3 Study to Investigate The Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of The Knee: A Randomized, Double-Blind, Placebo-Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks. |
ELI LILLY | 2025-04-22 |
| 33 | JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With A Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer. |
ELI LILLY | 2025-04-22 |
| 34 | A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse. |
ELI LILLY | 2025-04-22 |
| 35 | Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer’s Disease |
ELI LILLY | 2025-04-22 |
| 36 | A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3549492 Once Daily Compared With Placebo in Adult Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year. |
ELI LILLY | 2025-04-22 |
| 37 | A Master Protocol to Evaluate The Long-Term Safety of Pirtobrutinib PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study. |
ELI LILLY | 2025-04-22 |
| 38 | A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on A Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months. |
ELI LILLY | 2025-04-22 |
| 39 | A Phase 1 Trial Investigating LY4101174, An Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts – phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years. |
CRAIG GEDYE; | 2025-04-22 |
| 40 | A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate The Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months. |
ELI LILLY | 2025-04-22 |
| 41 | A Phase 2a, Single-Arm Study to Investigate The Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period. |
JOHN TESSER; | 2025-04-22 |
| 42 | A Phase 1/2, Dose-finding Study Investigating The Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening. |
ELI LILLY | 2025-04-22 |
| 43 | A Phase I, Randomized, Double-Blinded, Placebo-Controlled, 2-Part Study to Evaluate The Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of DC-853 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants. Participation could last up to 7 weeks |
ELI LILLY | 2025-04-22 |
| 44 | The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk. |
ELI LILLY | 2025-04-18 |
| 45 | A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate The Effect of Tirzepatide on The Reduction of Morbidity and Mortality in Adults With Obesity PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population. |
ELI LILLY | 2025-04-18 |
| 46 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Effect of Lepodisiran on The Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for A First Cardiovascular Event – ACCLAIM-Lp(a) PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). |
NOVA LAW; | 2025-04-18 |
| 47 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate The Effect of Retatrutide on The Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 Kg/m2 and Atherosclerotic Cardiovascular Disease And/or Chronic Kidney Disease PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor. |
PHILLIP MADONIA; | 2025-04-18 |
| 48 | EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With An Increased Risk of Recurrence PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years. |
MICHAEL MESHAD; | 2025-04-18 |
| 49 | A Master Protocol to Investigate The Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks. |
ELI LILLY | 2025-04-18 |
| 50 | A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer’s Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen. |
VICTORIA HORSTMAN; | 2025-04-18 |
| 51 | Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1 PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits. |
BELINDA SAVAGE-EDWARDS; | 2025-04-18 |
| 52 | A Master Protocol to Investigate The Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits. |
ELI LILLY | 2025-04-18 |
| 53 | A Randomized, Double-Blind, Phase 3 Study to Investigate The Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks. |
ELI LILLY | 2025-04-18 |
| 54 | A Phase 3, Multicenter, Open-Label Extension Study to Evaluate The Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3 PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria. |
WILLIAM SANDBORN; | 2025-04-18 |
| 55 | A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine – PIONEER-PEDS2 PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits. |
BELINDA SAVAGE-EDWARDS; | 2025-04-18 |
| 56 | A Master Protocol to Investigate The Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. |
APINYA VUTIKULLIRD; | 2025-04-18 |
| 57 | A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate The Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn’s Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn’s disease. |
ELI LILLY | 2025-04-18 |
| 58 | A Phase 3, Randomized, Double-Blind Study to Evaluate The Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks. |
ELI LILLY | 2025-04-18 |
| 59 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate The Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period. |
JAMES KRELL; | 2025-04-18 |
| 60 | A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in The Maintenance of Weight Reduction in Individuals With Obesity PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks. |
WAYNE HO; | 2025-04-18 |
| 61 | A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on A Background Therapy With Intranasal Corticosteroids PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months. |
WEILY SOONG; | 2025-04-18 |
| 62 | A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate The Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in The Course of Type 2 Diabetes PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early. |
ELI LILLY | 2025-04-18 |
| 63 | A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer. |
ELI LILLY | 2025-04-18 |
| 64 | Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for The Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. |
ALAINA VIDMAR; | 2025-04-18 |
| 65 | A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up. |
ARCHIE BOWIE; | 2025-04-18 |
| 66 | A Study of LOXO-783 Administered As Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With A PIK3CA H1047R Mutation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse. |
ELI LILLY | 2025-04-18 |
| 67 | A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess The Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months. |
ANDREW SHAROBEEM; | 2025-04-18 |
| 68 | A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits. |
LINDSAY ACKERMAN; | 2025-04-18 |
| 69 | A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate The Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits. |
ELI LILLY | 2025-04-18 |
| 70 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine – The REBUILD-2 Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period. |
BELINDA SAVAGE-EDWARDS; | 2025-04-18 |
| 71 | A Phase 3b, Randomized Controlled Study to Evaluate The Efficacy and Safety of Tirzepatide Once Weekly 5 Mg And/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction. |
ELI LILLY | 2025-04-18 |
| 72 | Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral Versus Placebo in Adolescent Participants Who Have Obesity, or Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months. |
CAREY CHRONIS; | 2025-04-18 |
| 73 | Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period. |
ELI LILLY | 2025-04-18 |
| 74 | PostMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare The Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on A CDK4 & 6 Inhibitor and Endocrine Therapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond. |
ELI LILLY | 2025-04-18 |
| 75 | A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate The Efficacy and Safety of LY3454738 in The Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD). |
ELI LILLY | 2025-04-18 |
| 76 | A Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits. |
ELI LILLY | 2025-04-18 |
| 77 | A Phase 1 Study of LY3200882 in Patients With Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors. |
ELI LILLY | 2025-04-18 |
| 78 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits. |
ELI LILLY | 2025-04-18 |
| 79 | A Master Protocol for A Randomized, Controlled, Clinical Platform Trial to Investigate The Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants. |
CAREY CHRONIS; | 2025-04-18 |
| 80 | A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate The Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin And/or SGLT2 Inhibitor PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits. |
MICHAEL QUADRINI; | 2025-04-18 |
| 81 | A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 visits. |
ELI LILLY | 2025-04-18 |
| 82 | An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for The Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC). |
TAREK HASSANEIN; | 2025-04-18 |
| 83 | A Randomized, Double-Blinded Study to Evaluate The Efficacy and Safety of Mevidalen in Patients With Alzheimer’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits. |
GANESH GOPALAKRISHNA; | 2025-04-18 |
| 84 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine – The REBUILD-1 Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period. |
BELINDA SAVAGE-EDWARDS; | 2025-04-18 |
| 85 | A Master Protocol for A Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate The Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn’s disease (CD). The study will last about 172 weeks and may include up to 44 visits. |
SOFIA VERSTRAETE; | 2025-04-18 |
| 86 | A Phase 4, Prospective, Open-Label, Single Arm Study to Assess The Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months. |
LINDSAY ACKERMAN; | 2025-04-18 |
| 87 | A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening. |
HEMANT PANDEY; | 2025-04-18 |
| 88 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose. |
LINDSAY ACKERMAN; | 2025-04-18 |
| 89 | A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks. |
YESSICA SACHDEVA; | 2025-04-18 |
| 90 | A Phase 3, Multicenter, Long-Term Extension Study to Assess The Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-severe atopic dermatitis. This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits. |
ELI LILLY | 2025-04-18 |
| 91 | Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period. |
JAMES KRELL; | 2025-04-18 |
| 92 | A Phase 1 Study of Oral LOXO-338, A Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years. |
ELI LILLY | 2025-04-18 |
| 93 | A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate The Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month. |
ELI LILLY | 2025-04-18 |
| 94 | A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn’s disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits. |
JEANNIE HUANG; | 2025-04-18 |
| 95 | A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate The Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period. |
ELI LILLY | 2025-04-18 |
| 96 | A Phase 1, Open-Label, Multiple-Dose Study to Investigate The Comparability of The Pharmacokinetics of Orforglipron (LY3502970) Single Capsule and Multiple Capsules in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess and compare a single capsule and multiple capsules of Orforglipron based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants under fasted and fed conditions. How the body handles and eliminates the study drug after meals and on an empty stomach will be measured. Information about any adverse effects experienced will be collected and the safety and tolerability of Orforglipron will also be evaluated. The study will last approximately 21 weeks, including a screening period. |
ELI LILLY | 2025-04-18 |
| 97 | Open-Label, Randomized Study With A Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib. |
DIEGO VIOLA; | 2025-04-18 |
| 98 | A Randomized, Investigator- and Participant-blinded, Multiple-ascending Dose, Placebo-controlled Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus and Healthy Japanese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening. |
YASUKO OWADA; | 2025-04-18 |
| 99 | A Multicenter, Phase 3, Open-Label Study to Investigate The Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC). |
JEANNIE HUANG; | 2025-04-18 |
| 100 | A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine As A Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma. |
ELI LILLY | 2025-04-18 |
| 101 | A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond. |
MICHAEL MANGUM; | 2025-04-18 |
| 102 | A Single- and Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer’s Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. The study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period. If the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period. |
BRANDON LENOX; | 2025-04-18 |
| 103 | A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess The Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With The Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without A Proton Pump Inhibitor in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations. |
ALEXANDER PREZIOSO; | 2025-04-18 |
| 104 | A Phase 1 Study of LY3484356 in Chinese Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a study of LY3484356 in Chinese participants with advanced breast cancer. Participants must have breast cancer that is estrogen receptor positive (ER+), HER2 negative (HER2-). The purpose of this study is to measure how much LY3484356 gets into the bloodstream and how long it takes the body to remove it. The safety and effectiveness of LY3484356 will also be studied. Participation could last up to 28 months. |
ELI LILLY | 2025-04-18 |
| 105 | A Randomized, Double-Blind, Phase 1 Study to Investigate The Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits. |
ELI LILLY | 2025-04-18 |
| 106 | An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period. |
JOEL NEUTEL; | 2025-04-18 |
| 107 | An Open-label, Single-arm, Multicenter, Phase 1 Study to Investigate The Pharmacokinetics, Safety, Tolerability, and Antitumor Activity of LY3537982 in Chinese Patients With KRAS G12C-Mutant Advanced Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in Chinese participants with KRAS G12C-mutant advanced solid tumors. The main purpose of this study is to determine how much of LY3537982 gets into the bloodstream and how long it takes the body to eliminate it in Chinese participants. The safety, tolerability and preliminary efficacy of LY3537982 will also be evaluated. Approximately 12 patients will be enrolled in this study. |
ELI LILLY | 2025-04-18 |
| 108 | A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for The Treatment of Chronic Pain PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing. |
ELYSA SHAW; | 2025-04-17 |
| 109 | A Phase 3, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. |
ELI LILLY | 2025-04-17 |
| 110 | A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits. |
ELI LILLY | 2025-04-17 |
| 111 | A Phase 3, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits. |
ELI LILLY | 2025-04-17 |
| 112 | A Phase 3, Randomized, Open-Label Study to Investigate The Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks. |
ELI LILLY | 2025-04-17 |
| 113 | A Phase 3, Randomized, Multicenter, Open-label Study to Investigate The Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits. |
ELI LILLY | 2025-04-17 |
| 114 | A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer’s disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period. |
JAMES SULLIVAN; | 2025-04-17 |
| 115 | EMBER: A Phase 1a/1b Study of LY3484356 Administered As Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer. |
ELI LILLY | 2025-04-17 |
| 116 | A Phase 3, Randomized, Open-Label Study to Investigate The Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks. |
ELI LILLY | 2025-04-17 |
| 117 | A Phase 3, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin And/or SGLT-2 Inhibitor PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits. |
ELI LILLY | 2025-04-17 |
| 118 | A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate The Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F. |
ELI LILLY | 2025-04-17 |
| 119 | An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA). |
CHRISTINE THAI; | 2025-04-17 |
| 120 | Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits. |
CHRISTOPHER CHOW; | 2025-04-17 |
| 121 | A Phase 3, Long-term Safety Study of LY3502970 in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone or in Combination With Oral Antihyperglycemic Medications (ACHIEVE-J) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication. This study includes 3 periods as follows: * screening and lead-in period: up to 4 weeks * treatment period: 52 weeks, including 20 weeks of dose escalation, and * safety follow-up period: 2 weeks. |
ELI LILLY | 2025-04-17 |
| 122 | A Phase 3, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems. |
ELI LILLY | 2025-04-17 |
| 123 | An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate The Safety and Efficacy of LY3541860 Compared to Placebo in Slowing The Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. |
SONIA KALIRAO; | 2025-04-17 |
| 124 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks. |
GILBERT JENOURI; | 2025-04-17 |
| 125 | A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks). |
RAKESH SAHAY; | 2025-04-17 |
| 126 | A Single- and Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson’s disease. |
STEVEN REYNOLDS; | 2025-04-17 |
| 127 | A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods. |
YESSICA SACHDEVA; | 2025-04-17 |
| 128 | A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose. |
FEDERICO LAHAM; | 2025-04-17 |
| 129 | A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate The Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period. |
ELI LILLY | 2025-04-17 |
| 130 | A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing’s sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond. |
ELI LILLY | 2025-04-17 |
| 131 | A Phase 1, Multicenter, Sequential-Design, Single-Dose, Open-Label Study of Lepodisiran in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, excluding screening. |
ELI LILLY | 2025-04-17 |
| 132 | A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 Mg and 4.5 Mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months. |
ELI LILLY | 2025-04-17 |
| 133 | A Randomized, Double-blind, Placebo-controlled Study to Investigate The Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes. |
YIMING MU; | 2025-04-14 |
| 134 | Investigating The Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer’s Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer’s disease (AD) and explore participant characteristics that might predict risk of ARIA. |
ELI LILLY | 2025-04-11 |
| 135 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate The Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda. |
ELI LILLY | 2025-04-11 |
| 136 | A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3305677 compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks. |
ELI LILLY | 2025-04-11 |
| 137 | EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years. |
ELI LILLY | 2025-04-08 |
| 138 | A First-in-Human, Phase 1a/1b Trial to Assess The Safety, Tolerability and Preliminary Efficacy of LY4170156, An Antibody-Drug Conjugate Targeting Folate Receptor Α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts – phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years. |
ELI LILLY | 2025-04-04 |
| 139 | A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to evaluate the safety, tolerability and PK of LY3876602 after administering it as single ascending doses and, following a data review, proceeding to multiple ascending doses in healthy participants. Blood tests will also be performed to check how much LY3876602 gets into the bloodstream and cerebrospinal fluid (CSF) and how long it takes the body to eliminate it. Following the screening visit for Part A, the study will last up to approximately 20 weeks., and a subgroup of participants will consent to CSF collections The study will last up to approximately 28 weeks for Part B. All participants will consent to CSF collections. |
ELI LILLY | 2025-04-04 |
| 140 | A Phase 1 Study to Investigate The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of LY4065967, to Evaluate The Effect of LY4065967 on The Pharmacokinetics of Rosuvastatin in Healthy Japanese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part. |
ELI LILLY | 2025-04-03 |
| 141 | A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate The Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks. |
CHAO CI; | 2025-04-02 |
| 142 | A Phase 1, Open-label, Randomized, Crossover Study to Assess The Effect of Food on The Pharmacokinetics of LY3866288 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 9 weeks including screening. |
ELI LILLY | 2025-04-01 |
| 143 | A Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer’s Disease and Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center. |
ELI LILLY | 2025-03-28 |
| 144 | A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using Investigational 1-mL and 2-mL Prefilled Syringes and Mirikizumab Test Solution Formulation Using Investigational 1-mL and 2-mL Prefilled Syringes in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via pre-filled syringe compared to mirikizumab (reference) solution given via pre-filled syringe. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening. |
ELI LILLY | 2025-03-28 |
| 145 | A Single Dose Study to Evaluate The Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days. |
JAMES SWAIN; | 2025-03-28 |
| 146 | KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events. |
ELI LILLY | 2025-03-25 |
| 147 | A Phase 3b, Randomized Controlled Study to Evaluate The Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 Mg in Adults Who Have Obesity or Overweight With Weight Related Comorbidities PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide 2.4 milligram (mg) in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 78 weeks. |
JORDAN VAUGHN; | 2025-03-24 |
| 148 | A Single-Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening. |
ELI LILLY | 2025-03-24 |
| 149 | A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have The PNPLA3 I148M Genotype PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B. |
ELI LILLY | 2025-03-20 |
| 150 | Single- and Multiple-Ascending Dose Study to Evaluate The Safety and Pharmacokinetics of LY3839840 Following Oral Dosing in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it’s processed in the body when given in different amounts. |
ELI LILLY | 2025-03-20 |
| 151 | An Open-Label, Study to Evaluate The Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab. |
ELI LILLY | 2025-03-19 |
| 152 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin. |
ELI LILLY | 2025-03-17 |
| 153 | A Phase I, Open-label, Fixed-sequence, Drug Interaction Study to Investigate The Effect of Multiple Oral Doses of Pirtobrutinib (LOXO-305) on The Pharmacokinetics of Repaglinide (CYP2C8 Substrate) in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) in adult healthy participants. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). The study is conducted in two periods. Participants will stay in this study for up to 54 days. |
ELI LILLY | 2025-03-17 |
| 154 | A Phase I, Open-label, Fixed-sequence, Drug Interaction Study to Investigate The Effect of Multiple Oral Doses of LOXO-305 on CYP1A2, CYP2C9, and CYP2C19 Substrates Using A Probe Drug Cocktail in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the effect of LOXO-305 on single oral dose of caffeine cytochrome P450 1A2 (CYP1A2) substrate, S-warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate) when administered as multiple doses by collecting the blood samples and conducting the blood tests to measure how much LOXO-305 is in the bloodstream and how the body handles and eliminates LOXO-305 in adult healthy participants. The study will also evaluate the safety and tolerability of LOXO-305. The study will be conducted in two periods. Participants will stay in this study for up to 67 days, including screening. |
ELI LILLY | 2025-03-10 |
| 155 | A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years. |
ELI LILLY | 2025-03-07 |
| 156 | A Multiple Dose Combination Study to Evaluate The Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks. |
ELI LILLY | 2025-03-07 |
| 157 | A Phase I, Open-Label, Randomized, 2-Way Crossover Study to Investigate The Effect of Food on The Pharmacokinetics of A Single Oral Dose of Pirtobrutinib (LOXO-305) in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) after meals and on an empty stomach. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). Participants will stay in this study for up to 53 days (screening through follow-up call). |
ELI LILLY | 2025-03-07 |
| 158 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation. |
ELI LILLY | 2025-03-06 |
| 159 | A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of LY3885125 to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Ascending Dose in Participants with Dyslipidemia and Repeat-Doses in Participants with NAFLD PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with non-alcoholic fatty liver disease (part B). Blood tests will be performed to check how much LY3885125 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 49 weeks for part A and 62 weeks for part B, for a total of approximately 111 weeks. |
ELI LILLY | 2025-03-06 |
| 160 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis. |
ELI LILLY | 2025-03-05 |
| 161 | A Bioequivalence Study of Injections of Mirikizumab Solution Using Investigational 1-mL and 2-mL Pre-Filled Syringes and Investigational 1-mL and 2-mL Autoinjectors in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening. |
ELI LILLY | 2025-03-04 |
| 162 | A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer. |
ELI LILLY | 2025-03-03 |
| 163 | A Multiple-Dose Study to Investigate The Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period. |
ELI LILLY | 2025-03-03 |
| 164 | A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B. The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in those participants whose disease progressed on ramucirumab and gefitinib and that have T790M – positive metastatic NSCLC. |
ELI LILLY | 2025-03-03 |
| 165 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating The Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis. |
ELI LILLY | 2025-03-03 |
| 166 | A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer. |
ELI LILLY | 2025-03-03 |
| 167 | Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine As First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer. |
ELI LILLY | 2025-03-03 |
| 168 | An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old. |
ELI LILLY | 2025-03-03 |
| 169 | Master Rollover Protocol for Continued Safety Assessment of Study Drug Related Papers Related Patents Related Grants Related Experts Highlight: This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment. |
PARVIN FATHEDDIN PEDDI; | 2025-03-03 |
| 170 | A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis. |
ELI LILLY | 2025-02-28 |
| 171 | A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA). |
AMER AL KHOUDARI; | 2025-02-28 |
| 172 | A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate The Efficacy and Safety in Overweight or Obese Men and Women PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women |
ELI LILLY | 2025-02-28 |
| 173 | MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, A CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant. |
ELI LILLY | 2025-02-28 |
| 174 | A Phase 1 Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 16 study visits. |
ARCHIE BOWIE; | 2025-02-28 |
| 175 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, A CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer. |
ELI LILLY | 2025-02-28 |
| 176 | A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib As First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After An 8-Week Lead-In Treatment With Erlotinib PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone. Participants will have Non-Small Cell Lung Cancer (NSCLC) that has advanced to Stage IV. Participants should not have been treated with drugs for Stage IV NSCLC, previously. All participants will get erlotinib alone, for approximately 8 weeks. Participants with radiographic disease control at the end of the erlotinib lead-in study period will be randomly assigned to receive LY2875358 plus erlotinib or erlotinib alone. Participants, who were chosen to receive erlotinib, alone, may cross over to the combination treatment at the time of progression. |
ELI LILLY | 2025-02-28 |
| 177 | A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it. The study is conducted in two parts (part A and B), each part has a separate treatment cohort. The study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period. |
AHAD SABET; | 2025-02-28 |
| 178 | A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction. |
ELI LILLY | 2025-02-28 |
| 179 | A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single-ascending Dose and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4005130 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it. Part A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for the multiple-ascending doses (MAD) of the study will either last about 16 weeks with 13 visits or 20 weeks with 12 visits not counting the time for screening. |
ARCHIE BOWIE; | 2025-02-28 |
| 180 | A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib. |
ELI LILLY | 2025-02-28 |
| 181 | A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks. |
ELI LILLY | 2025-02-28 |
| 182 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, A CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. |
ELI LILLY | 2025-02-28 |
| 183 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate The Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months |
STEVEN WEINSTEIN; | 2025-02-28 |
| 184 | A Single Ascending and Multiple Dose Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of LY3873862 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of LY3873862 when administered either in single or multiple doses in healthy participants. The study will also assess how fast LY3873862 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 58, 72, and 72 days for Part A, B, and C, respectively. |
DENISA WILKES; | 2025-02-28 |
| 185 | A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer’s Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part. |
STEVEN REYNOLDS; | 2025-02-28 |
| 186 | A Drug-Drug Interaction, Single-arm, Open-label Study to Assess The Effect of Quinidine on The Pharmacokinetics of Orforglipron in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants. The study will last up to approximately 8 weeks including screening. |
ELI LILLY | 2025-02-28 |
| 187 | A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond. |
ELI LILLY | 2025-02-28 |
| 188 | Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab. |
ELI LILLY | 2025-02-27 |
| 189 | A Long-term Study to Assess The Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months. |
ELI LILLY | 2025-02-27 |
| 190 | LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab As Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib. |
ELI LILLY | 2025-02-27 |
| 191 | A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation. |
ELI LILLY | 2025-02-27 |
| 192 | An Open-Label, 24-Week Study to Investigate The Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color. |
ELI LILLY | 2025-02-27 |
| 193 | A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years. |
ELI LILLY | 2025-02-27 |
| 194 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With An Open-Label Extension Assessing The Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire. |
ELI LILLY | 2025-02-26 |
| 195 | A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for The Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period. |
ELI LILLY | 2025-02-24 |
| 196 | A Phase I, Single-Dose, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, 3-Way Crossover Study to Evaluate The Effect of LOXO-305 on QTc Interval in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on the heart rate-corrected QT (QTc) interval and to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib. The study will also evaluate the safety and tolerability of pirtobrutinib. The study will last up to 71 days, including screening. |
ELI LILLY | 2025-02-24 |
| 197 | A Phase I, Open Label, Fixed-sequence Drug Interaction Study to Investigate The Effect of Multiple Oral Doses of LOXO-305 on The Pharmacokinetics of A Single Dose of Intravenous and Oral Midazolam (CYP3A4 Substrate) in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. The study will also access how much endogenous coproporphyrins I and III as biomarkers of OATP1B1 and OATP1B3 is in the bloodstream and how the body handles and eliminates them following single and multiple oral doses of Pirtobrutinib. Safety and tolerability of Pirtobrutinib will also be evaluated. For each participant, the total duration of the study will be 59 days, including screening. |
ELI LILLY | 2025-02-24 |
| 198 | A Phase I, Open-label, Fixed-sequence, Drug Interaction Study to Investigate The Effect of Single and Multiple Oral Doses of LOXO-305 on The Pharmacokinetics of Multiple Oral Doses of Digoxin (P-Glycoprotein Substrate) in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting the blood tests to measure how much digoxin is in the bloodstream and how the body handles and eliminates it in healthy participants. The study will also evaluate the safety and tolerability of Pirtobrutinib. Participants will stay in this study for up to 58 days, including screening. |
ELI LILLY | 2025-02-21 |
| 199 | A 24-week Multicenter, Open-label, Single-arm Study to Evaluate Safety in Patients With Type 2 Diabetes Mellitus in India Treated With Dulaglutide PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India. |
ELI LILLY | 2025-02-20 |
| 200 | Zyprexa® Relprevv™ Patient Care Program PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS). |
ELI LILLY | 2025-02-13 |